Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk looks like a business with very strong operating profitability, but no longer like an obvious “cheap” market story. A P/E ratio of 11.0 is noticeably below the industry median, which supports the valuation and suggests a relatively moderate earnings price; however, P/S, P/B, and P/FCF are above industry benchmarks, so part of the quality is already priced into the shares. ROE, ROA, ROI, and return on tangible equity are especially strong: all are significantly above the median and remain at very high levels, confirming capital efficiency and sustainable profitability. Margins are also impressive: gross margin, operating margin, and net profit margin are significantly above the industry, and their year-by-year trend is generally stable, with no signs of a sharp deterioration. At the same time, the quick ratio and current ratio remain weak and below industry levels, indicating limited short-term liquidity and warranting caution. Debt/equity is above the median, and long-term debt has increased noticeably compared with earlier periods, so leverage is not a strong point of the model. On the other hand, absolute figures for revenue, EBITDA, operating profit, and net profit are growing, while equity is increasing, which supports the company’s fundamental value. Gross profit and operating income also show solid scale and an improving earnings base, which is important for a long-term investor. Dividend yield remains moderate and is not the main driver of the investment case, so its contribution to revaluation is limited. Overall, the picture is rather positive, but not strong enough to aggressively raise the target price: high profitability and business growth are offset by expensive valuation multiples and weak liquidity. Therefore, the adjustment should be small and conservative, reflecting the quality of the business while taking into account that the market has already partially priced in this fundamental strength.

Novo Nordisk A/S

Сильный индекс, без изменений. Быки крепко уверены в своих позициях.

Strong index, flat. The bulls are very confident in their positions.

Сильный индекс, незначительно упал. Рынок не поддерживает быков.

Strong index, slightly down. The market does not support the bulls.

Сильный индекс, без изменений. Отток средств из лонгов на высоком уровне.

Strong index, flat. Outflow of funds from longs at a high level.

Novo Nordisk's strong profitability and growth support its valuation, but high P/B and P/S ratios and weak liquidity limit the potential for upward revision.

Key Points
AbbVie is successfully transitioning its revenue base toward newer immunology drugs to offset the loss of patent protection for Humira.
Novo Nordisk maintains a dominant position in the rapidly expanding global markets for diabetes and obesity treatments.
Which healthcare powerhouse is the better fit for your portfolio in 2026?
The healthcare sector is shifting as legacy blockbusters face competition from low-cost generics while new chronic care treatments explode. Choosing between AbbVie Inc (NYSE:ABBV) and Novo Nordisk A/S (NYSE:NVO) requires weighing diversification against specialized growth.
AbbVie is a broad biopharmaceutical giant with a diverse lineup of immunology and oncology drugs. Novo Nordisk focus is narrower, leading the world in metabolic health through its diabetes and obesity therapies. Both are high-profile pharmaceutical stocks, but they offer very different risk and reward profiles for retail investors.
AbbVie functions as a diversified pharmaceutical company that develops and sells therapies for immunology, oncology, and aesthetics. Its primary customers include hospitals, government agencies, and specialty pharmacies, though its U.S. sales are concentrated among three major wholesale distributors. McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH), and Cencora Inc (NYSE:COR) represent significant distribution partners, and customer concentration like this adds a layer of risk to the business.
In FY 2025, revenue reached $61.2 billion, representing revenue growth of just about 8.7% compared to the previous year. The company reported net income of $4.2 billion for the same period. This resulted in a net margin around 7%, which measures how much of each dollar in revenue is kept as profit after all expenses are paid.
As of its December 2025 balance sheet, the debt-to-equity ratio is negative 21x, indicating that total liabilities exceed shareholder equity. The so-called current ratio is 0.7x, which suggests the company has $0.70 in short-term assets for every dollar of short-term debt. Free cash flow totaled $17.8 billion in FY 2025, which is the cash left over after paying for operations and purchasing equipment or other assets.
The case for Novo Nordisk
Novo Nordisk A/S focuses its strategy on chronic disease care, specifically in the areas of diabetes and obesity. The company serves more than 45 million people worldwide and operates production sites across multiple continents, including North America and Europe. Unlike many of its peers, the company does not disclose specific major customer concentrations in its latest filings, suggesting a more fragmented customer base.
In FY 2025, revenue reached $48.2 billion (the company reports in Danish kroner; the figures have been converted to U.S. dollars), an increase of more than 6% over the prior year. Net income for the year was nearly $16 billion, which is the total profit remaining after all costs and taxes. This performance resulted in a net margin of 33%, showing that the company retains a high percentage of its sales as profit.
As of its December 2025 balance sheet, the debt-to-equity ratio is 0.7x. This means the company holds roughly $0.70 of debt for every dollar of equity held by shareholders. Novo's current ratio is 0.8x, and free cash flow for the year reached approximately $4.5 billion. Free cash flow is a critical measure of the cash a company generates after accounting for the money spent to maintain or expand its asset base.
Risk profile comparison
AbbVie faces significant risks from patent expirations and the introduction of generic competition for Humira, its former top-selling drug. Revenue is increasingly concentrated in two newer drugs, Skyrizi and Rinvoq, which combined for approximately 42% of total sales in 2025. Additionally, the company is managing pricing pressure from the Inflation Reduction Act and the high failure rate inherent in developing new pharmaceutical therapies.
Novo Nordisk A/S operates in a highly competitive market where manufacturing capacity and supply chain efficiency are constant challenges. The company must navigate intense competition from other drug manufacturers and potential pricing regulations on insulin and weight-loss medications. Furthermore, the company faces risks related to the clinical trial process, where unexpected side effects or a lack of efficacy could prevent new treatments from reaching the market.
Valuation comparison
Novo Nordisk A/S currently trades at lower multiples than AbbVie, suggesting a more conservative valuation relative to its future earnings estimates and annual sales.
Metric
AbbVie
Novo Nordisk A/S
Forward P/E
16.1x
13.8x
P/S ratio
7.2x
3.9x
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy in 2026?
AbbVie has a drug pipeline that some on Wall Street believe could include blockbusters (more than $1 billion in lifetime revenue) for treating schizophrenia, Parkinson's disease, psychosis from Alzheimer's, and certain solid tumors.
On top of that, the business is buying itself additional growth with its recent deal to acquire Apogee Therapeutics. Its two relatively new immunology products, Skyrizi and Rinvoq, have proven to be true growth drivers for the business, and investors are hopeful that an FDA decision on a Parkinson's treatment later this year will bode well for the company. AbbVie is expected to see screaming growth in net income this year, from $4.2 billion to $14.6 billion. Sales should grow to $67.2 billion.
Novo Nordisk, meanwhile, has the blockbuster drugs Wegovy and Ozempic (the same drug marketed for different purposes) but faces investor doubts about its market position given a deal with the federal government to lower prices for the GLP-1s, the emergence of generic competitors, and the apparent advances by Eli Lilly & Co (NYSE:LLY) in developing weight loss drugs expected to be superior to Novo's offerings.
Still, the introduction of the once a day Wegovy pill in the U.S. has been a resounding success and the business has a patent on injectable Ozempic/Wegovy till 2032, providing it some competitive moat. Still, Wall Street sees sales declining in fiscal 2026 by about 3% with net income contracting 4% as pricing pressures erode margins just a bit. Longer-term, analysts expect the company to reverse the 2026 decline and start growing again as new products come on line.
It's hard to say don't buy the company that invented the GL-1 market, but AbbVie's near-term, growth is so impressive it is worth paying the slightly pricier premiums on its P/S and forward P/E ratios and waiting to see how Novo Nordisk adjusts to heightened competition.
Should you buy stock in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $410,024!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,372,815!*
Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 10, 2026.
Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Eli Lilly, and Novo Nordisk. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Pfizer PFE stock has risen 8.6% in the past three months as investors have gained confidence in the company’s ability to stabilize earnings and offset the continued decline in COVID-19 product sales. A key catalyst has been a solid second-quarter performance, which showed that higher revenue from non-COVID products more than offset declining sales of its COVID products –Comirnaty (COVID-19 vaccine - in partnership with BioNTech [BNTX]) and Paxlovid (oral antiviral). Excluding sales from BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer also raised the lower end of its 2026 revenue guidance, backed by continued strong performance of its new and acquired products.
The shares hit a fresh 52-week high on Sept. 3, 2026, reflecting a meaningful improvement in sentiment after years of pressure. Investors are increasingly looking beyond the COVID revenue decline toward Pfizer’s newer growth drivers, including oncology and other acquired assets and the company's pipeline and cost-cutting efforts.
However, to make an informed decision on whether to buy, sell or hold the stock, it is important to assess Pfizer’s fundamentals by weighing its key strengths against the risks and challenges it faces.
Pfizer’s Non-COVID Products Fueling Its Next Growth Phase
Pfizer's business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products. However, the company is gradually diversifying its portfolio through a combination of internal product launches like Abrysvo, Zavzpret, Elrexfio, Hympavzi, Litfulo and others, strategic acquisitions like Seagen, Metsera and Biohaven and the continued growth of several established brands like Vyndaqel, Padcev and Eliquis.
Pfizer expects its recently launched and acquired products to record continued double-digit growth. Reflecting this trend, sales from these products increased 22% operationally in the first quarter of 2026 and 18% in the second quarter.
Pfizer’s Oncology Portfolio Poised for Continued Growth
Pfizer is one of the world’s leading oncology drugmakers with a broad portfolio of marketed cancer therapies as well as a deep oncology pipeline spanning multiple treatment modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
Oncology sales comprise around 27% of its total revenues. Its oncology revenues grew 5% in the first half of 2026, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer considers Padcev to be a potential growth driver in the oncology segment and plans to invest in this asset.
Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. It is also advancing its oncology clinical pipeline across areas such as breast, thoracic, gastrointestinal and blood cancers. Several oncology candidates have entered late-stage development, such as atirmociclib (a selective CDK4 inhibitor for HR-positive/HER2-negative breast cancer), sigvotatug vedotin (an antibody-drug conjugate for first-line metastatic non-small cell lung cancer) and mevrometostat (an EZH2 inhibitor being developed in combination with enzalutamide for prostate cancer).
A key candidate in its oncology pipeline is PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from Chinese biotech 3SBio in 2025. Pfizer has initiated nine studies, including two pivotal phase III studies for PF-08634404 in first-line metastatic colorectal cancer and first-line NSCLC. Pfizer aims to establish PF-08634404 as a potential backbone therapy across multiple tumor types. By 2030, Pfizer expects to have eight or more blockbuster oncology medicines in its portfolio.
PFE Targets Obesity Market With Ambitious Phase III Program
The company is rebuilding its pipeline in oncology and obesity, which it believes can drive growth in 2028 and beyond. Pfizer plans an extensive phase III program for berobenatide, its monthly GLP-1 receptor agonist added from last year’s Metsera acquisition. In 2026. Pfizer plans 10 phase III studies for berobenatide for obesity and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea. Three phase III studies on berobenatide have already begun. Pfizer is targeting the first of a series of potential approvals for berobenatide in 2028. Pfizer is also evaluating berobenatide in combination with an amylin-based therapy, PF'3945, in phase II studies. However, in the obesity space, Pfizer lags far behind leaders like Eli Lilly LLY and Novo Nordisk NVO.
PFE’s COVID Business Faces Continued Revenue Declines
During the pandemic, Pfizer generated extraordinary COVID-related sales from Comirnaty and Paxlovid. Those revenues have fallen sharply as the pandemic faded.
Sales of Pfizer’s COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 and $6.7 billion in 2025 from $56.7 billion in 2022. Sales of Comirnaty are declining due to a narrow recommendation for COVID vaccines in the United States, while Paxlovid is experiencing reduced demand from lower infection rates.
In 2026, Pfizer expects COVID-related revenues of approximately $4 billion, down from its previous forecast of $5 billion and below $6.7 billion generated in 2025. The decline reflects the continued normalization of COVID-19 infection rates and lower demand for COVID products. Consistent with this trend, sales of both Comirnaty and Paxlovid declined significantly during the first half of 2026.
PFE’s LOE Headwinds
Pfizer faces a significant patent cliff later this decade. Pfizer expects a significant negative impact on revenues from the loss of exclusivity (LOE) cliff in the 2026-2030 period as several of its key products, including Eliquis, Ibrance, Xeljanz and Xtandi, face patent expirations. The LOE cliff is expected to hurt sales by approximately $1.1 billion in 2026.
Pfizer’s 2026 Guidance Points to Sluggish Growth
Pfizer’s revenue guidance for 2026 indicates mostly flat to slightly negative year-over-year growth.
Pfizer expects total revenues for 2026 to be between $60.5 billion and $62.5 billion. The range represents a slight decline from 2025 revenues of $62.6 billion due to lower revenues from COVID products, Comirnaty and Paxlovid, and loss of revenues from the upcoming patent cliff.
In 2026, Pfizer expects adjusted earnings per share in the range of $2.80-$3.00, which represents a decline from the 2025 EPS of $3.22 due to the dilutive impact of 3SBio and Metsera deals, lower COVID revenues and higher taxes.
PFE Stock’s Price, Estimates & Valuation
The stock has risen 11.6% so far this year compared with an increase of 14.5% for the industry.
PFE Stock Underperforms Industry
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry. Going by the price/earnings ratio, Pfizer’s shares currently trade at 9.42 forward earnings, significantly lower than 18.70 for the industry but slightly above the stock’s five-year mean of 9.25. The stock is also trading below most large drugmakers like Lilly, Novo Nordisk, AstraZeneca, AbbVie, J&J and others.
PFE Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has risen from $2.97 to $2.98, while that for 2027 has risen from $2.86 to $2.94 over the past 60 days.
PFE Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in PFE Stock
Pfizer is navigating a difficult transition following the sharp decline in COVID-related sales from Comirnaty and Paxlovid. The market is concerned about Pfizer’s ability to replace declining COVID-related revenues and offset upcoming patent expirations through new product launches, pipeline development and contributions from acquisitions.
Although Pfizer’s 2026 sales guidance indicates minimal growth, the company expects a high single-digit revenue CAGR for five years, starting from year-end 2028. Pfizer expects its recently launched and acquired products, along with a strong pipeline, to help it return to growth from 2029 onward.
Pfizer's valuation is relatively inexpensive compared with many large pharmaceutical peers, and the stock offers one of the highest dividend yields in the sector. Pfizer’s dividend yield stands at around 6.2%
Pfizer’s significant cost reduction and efforts to improve R&D productivity measures are also driving profit growth. Pfizer expects approximately $9.7 billion in total net savings from its productivity enhancement initiative through 2029.
Long-term investors may consider retaining this Zacks Rank #3 (Hold) stock and can wait and see if Pfizer can successfully execute on its strategy and generate meaningful growth from its newer assets and restore revenue growth. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).

Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?

Key Points
Novo Nordisk was first to market with a GLP-1 weight-loss drug, but lost the lead to Eli Lilly.
Novo Nordisk has been working hard to regain lost market share in the GLP-1 space.
Using traditional valuation metrics, Novo Nordisk's stock looks cheap.
GLP-1 weight-loss drugs burst onto the scene when Novo Nordisk (NYSE: NVO) introduced Wegovy to the world. There was so much demand that the drug maker couldn't keep up. That shows the opportunity that this new class of weight-loss drugs offers, but it also explains why Novo Nordisk, while first to market, isn't the industry leader today. That title goes to Eli Lilly (NYSE: LLY).
After a massive decline of over 66% from its 2024 high, traditional valuation metrics suggest Novo Nordisk's stock is cheap. However, the bigger question you need to consider is the pharmaceutical company's ability to compete against Eli Lilly's now-dominant GLP-1 drugs. Here's a quick look at what you need to know about Novo Nordisk before you buy it.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
There is always a competitor looking to knock you off your perch
Two of the most important things to understand about the pharmaceutical sector are that it is intensely competitive and driven by innovation. Just because a company has a blockbuster drug doesn't mean it has a lock on a medical condition. There's also the small issue of patent protection, which is time-limited for new drugs. So, even in the best-case scenario, a drug maker can only expect to generate outsize profits from a successful drug for a short period.
That's the backdrop within which you have to view Novo Nordisk. Yes, it was the first company to market with a GLP-1 weight-loss drug, but it quickly lost its lead to Eli Lilly. That's a big reason why investor sentiment has turned against Novo Nordisk. But Wall Street has a habit of going too far. This is where traditional valuation metrics come in for Novo Nordisk.
The stock's price-to-sales ratio is 4x as of this writing compared to a five-year average of 8.6x. Its price-to-earnings ratio is 11.6x compared to a five-year average of 25.1x. And its price-to-book ratio is 6.1x versus a longer-term average of 16.4x. By comparison, using the valuation metric that most investors lean on, the average drug maker's P/E is 26.5x.
From this perspective, Novo Nordisk does, in fact, look attractively priced. Value-focused investors would probably find it interesting. But add in a 3.7% dividend yield and a payout ratio below 40%, and the story could be attractive for dividend lovers, too.
Can Novo Nordisk get back in the game?
The problem here is that Novo Nordisk is in the middle of a transition period. First, the company is attempting to use its new GLP-1 pill to regain share in the GLP-1 weight-loss space. The Wegovy pill is seeing strong early success, but it remains unclear whether it will be enough to improve Novo Nordisk's competitive position against industry leader Eli Lilly, which has also recently introduced a GLP-1 pill.
Second, Novo Nordisk is attempting to change to a volume-driven model. That has meant lowering prices on its GLP-1 drugs in an effort to get more customers to use them. In the short term, this has resulted in weakness in revenue and earnings. As with the company's new pill, it is unclear whether a focus on volume will work out as hoped. In other words, there remains a significant amount of uncertainty.
Is Novo Nordisk worth buying?
Value investors and dividend investors should probably take a deep dive into Novo Nordisk. There is a lot of uncertainty right now as the company, effectively, attempts to turn its business around in the GLP-1 space. However, it is a well-respected drugmaker offering innovative products in a niche health area (weight loss) with significant long-term potential. Even if it doesn't unseat Eli Lilly from its GLP-1 lead, Novo Nordisk should still be able to generate significant revenues and earnings, and support an attractive yield. Given its valuation, the risk/reward balance is probably leaning toward reward right now. In other words, Novo Nordisk is, indeed, too cheap to ignore.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 8, 2026.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Novo Nordisk NVO announced positive data from the phase III STEP Young study evaluating once-weekly subcutaneous semaglutide, in combination with a reduced-calorie diet and increased physical activity, in children with obesity aged six to under 12 years.
More on the STEP Young Study Data
The phase III STEP Young study met its primary endpoint by demonstrating a greater reduction in body mass index (BMI) at week 68 following treatment with semaglutide versus placebo. Both treatment groups received lifestyle modification, including a reduced-calorie diet and increased physical activity.
Importantly, 40.4% of children who were treated with once-weekly subcutaneous semaglutide were no longer classified as having obesity after week 68, compared with none in the placebo group. More than 85% of children had class II or III severe obesity at baseline.
Per the company, two out of five children treated with semaglutide reduced their BMI below the obesity threshold, reaching either a normal-weight or overweight classification, compared with none of the children receiving placebo.
The overall safety and tolerability profile of semaglutide seen in the STEP Young study was consistent with prior pediatric and adult studies, with no new safety concerns reported.
The company plans to present detailed data from the phase III STEP Young study at the Obesity Society’s annual meeting in November.
NVO’s Price Performance
Year to date, shares of Novo Nordisk have declined 5.3% against the industry’s rise of 16.4%.
Image Source: Zacks Investment Research
NVO Thrives on Semaglutide-Based Medicines
Novo Nordisk markets its semaglutide-based medicines under the brand names Ozempic (injection and oral pill) and Rybelsus (oral tablet) for type II diabetes (T2D), and Wegovy (injection and oral pill) for chronic weight management.
The company’s semaglutide-based medicines continue to demonstrate benefits beyond blood sugar control and weight loss, including reducing cardiovascular (CV) risk and improving kidney disease outcomes.
Novo Nordisk has been witnessing strong success with its GLP-1 medicines, Wegovy for obesity and Ozempic and Rybelsus for T2D.
In the first half of 2026, total reported Obesity care sales increased 20% year over year in DKK, or 24% at constant exchange rates, driven by higher sales across the Wegovy portfolio, including incremental sales from the newly launched Wegovy pill.
In late December, the FDA approved NVO’s 25 mg oral semaglutide (Wegovy pill) for obesity and CV disease, which was subsequently launched in early January. The Wegovy pill is also approved in the EU.
NVO Faces Rising Competitive Pressure
Novo Nordisk faces intense competition from Eli Lilly LLY in the obesity market. Lilly's Mounjaro for T2D and Zepbound for obesity have earlier demonstrated superior weight-loss efficacy in clinical studies, allowing the company to gain market share steadily. Despite being on the market for a shorter duration, these drugs have become LLY’s key top-line drivers.
Lilly has also secured FDA approval for its oral GLP-1 drug, orforglipron, for adults with obesity or overweight with weight-related medical problems, marketed under the brand name Foundayo.
While Novo Nordisk and Eli Lilly currently dominate this space, smaller biotechs like Structure Therapeutics GPCR and Viking Therapeutics VKTX are also advancing GLP-1–based therapies for treating obesity.
Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist (RA), VK2735, is being developed in both oral and subcutaneous formulations for the treatment of obesity. VKTX plans to advance oral VK2735 into phase III development for obesity in the fourth quarter of 2026.
Structure Therapeutics’ phase II ACCESS program on its orally administered small molecule GLP-1 RA, aleniglipron, demonstrated significant weight loss across all doses. Based on such encouraging results, GPCR has initiated dosing patients in its late-stage ACCOMPLISH program to evaluate aleniglipron for chronic weight management.
NVO Zacks Rank
Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

Key Points
The stocks listed here have all declined by double-digits over the past year.
However, they still possess some attractive long-term growth opportunities.
At reduced valuations, they are much more compelling investment options to consider right now.
Investing in an underperforming growth stock can be a great move for long-term investors. If a stock is trading at a low earnings multiple and there aren't serious issues with the underlying business, it can be a sign that the market may have overreacted to company or even industry-related developments.
It's these types of opportunities that can lead to significant gains down the road for investors who are willing to be patient and hang on. Three growth stocks trading below $100 that I believe are great buys right now are Netflix (NASDAQ:NFLX), Uber Technologies (NYSE:UBER), and Novo Nordisk (NYSE:NVO).
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
Netflix
Streaming giant Netflix has been struggling this year, amid questions about its future growth. The company is still generating double-digit growth, but with growing competition in the video streaming industry, the market appears less convinced of Netflix's future success.
As a result, Netflix's stock is down 17% this year, at one point falling as low as $65. On Friday, it closed at just over $78, and simply getting back to $100 would require a sizable 28% rally from its current level.
Netflix is, however, one of the better growth stocks to buy at under $100 as it provides investors with exposure to a top streaming company, which generates strong profit margins and has proven it can grow in many different ways, even as it has broadened its business to include live sports and gaming.
At 25 times its trailing earnings, Netflix is an excellent growth stock to buy today.
Uber Technologies
Shares of Uber are down around 18% over the past year. It has been an underperforming stock, but what's encouraging is that the business also has plenty of long-term growth opportunities to tap into.
In addition to continuing to grow its operations into more international markets, Uber has also partnered with multiple companies as it looks to be a big player in the robotaxi industry, recently launching a service in London, in partnership with a British technology company, Wayve.
The tech stock is trading at around $76, and its price-to-earnings (P/E) multiple of 17 looks incredibly attractive given how much potential room there still is for Uber's business to grow. In the trailing 12 months, the company has generated more than $55 billion in revenue, with its net income totaling a solid $9.6 billion.
Novo Nordisk
Healthcare giant Novo Nordisk has been struggling to win over investors as rival Eli Lilly has been dominating the GLP-1 drug market. However, with a top name in Ozempic and a higher-dose version of Wegovy showing it can potentially go toe-to-toe with Eli Lilly's leading product, there's still plenty of hope for Novo Nordisk stock to recover.
It's trading at around $47, and the stock is deeply discounted, as its P/E multiple is a lowly 11, suggesting that investors aren't giving it much of a chance. At such a low multiple, there's an appealing margin of safety that comes with the healthcare stock, and it may have plenty of room to rise higher if it can prove its doubters wrong.
The company has been facing challenges, largely due to rising competition. However, this is a stock that I think the market is dead wrong about, because Novo Nordisk still has some promising assets in its portfolio, and there is room for multiple drugs to perform well in the massive GLP-1 market.
Novo Nordisk's stock may be down, but I wouldn't count it out for the long run; now may be a great time to buy it while its valuation is incredibly low. As a bonus, it also offers a fairly high yield of around 3.9%.
Should you buy stock in Netflix right now?
Before you buy stock in Netflix, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Netflix wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 8, 2026.
David Jagielski, CPA has positions in Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly, Netflix, and Novo Nordisk. The Motley Fool recommends Uber Technologies. The Motley Fool has a disclosure policy.

3 of the Best Growth Stocks to Buy for Less Than $100 Right Now

Key Points
Eli Lilly's most important drugs right now are Mounjaro, Zepbound, and, to a lesser degree, Foundayo.
The company's dominant GLP-1 weight-loss drugs are facing material competition and have time-limited patent protection.
Eli Lilly is attempting to build its drug pipeline with acquisitions, which is another big story to watch, even if the deals aren't impactful right now.
Eli Lilly's (NYSE: LLY) success in the GLP-1 weight-loss space highlights one of the biggest risks it faces right now. And it helps explain why the company leading the GLP-1 race is working so hard to acquire smaller drugmakers to broaden its drug pipeline. The truth is, Eli Lilly's latest deals probably won't boost its stock right now, but they could be the foundation that builds the pharmaceutical giant's future. Here's what you need to know.
What does Eli Lilly do?
If you look at Eli Lilly's second-quarter revenues, you come away with a very clear picture of the pharmaceutical company's business. Mounjaro, Zepbound, and Foundayo account for nearly two-thirds of the company's top line. That's a huge number when you consider that all of these drugs are targeted at the same health issue: weight loss. But Eli Lilly isn't really a weight-loss company; it is a drug maker. It just happens that its weight-loss drugs have become incredibly important products.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
What's interesting is that Eli Lilly wasn't the first to market with a weight-loss drug in the emerging GLP-1 space. The first company was Novo Nordisk (NYSE: NVO), with Wegovy. But Novo Nordisk struggled to keep up with demand, and Eli Lilly's Mounjaro and Zepbound shots appear to be more effective than Wegovy shots. Eli Lilly very quickly took the lead.
That's important to remember because it highlights the very real threat of new products in the pharmaceutical space displacing existing ones. Healthcare is an intensely competitive sector driven by innovation. Just because Eli Lilly is on top today does not mean it will remain there forever. Notably, Novo Nordisk beat Eli Lilly to market with a GLP-1 pill, and other companies, such as Pfizer (NYSE: PFE), are working on weight-loss drugs of their own. Eli Lilly is still the GLP-1 leader, but it knows it has to be prepared for the day when that's no longer the case.
Eli Lilly's dominance was always going to end
The interesting thing here is that Eli Lilly's GLP-1 drugs could remain the leading option, and the company would still see its leading position come to an end. That's because drugs have limited patent protection, with competitors allowed to produce generic versions of successful drugs after a set number of years. This is just how the drug sector works. Eli Lilly knows this and has been using the profits from its highly successful GLP-1 drugs to invest for the future.
Most recently, it agreed to acquire Merida Biosciences, a biotechnology company focused on the autoimmune and allergy spaces. The all-cash deal could cost as much as $2.875 billion if Merida Biosciences hits contractual development milestones. Right now, however, this deal isn't all that important to Eli Lilly's sales and earnings. But that doesn't mean it isn't important.
Merida Biosciences is just one of many acquisitions Eli Lilly has made over the last year or so. It has also acquired or agreed to acquire AtaiBeckley (NASDAQ: ATAI), which operates in the mental health space; Centessa Pharmaceuticals, which focuses on sleep-wake disorders; and Curevo, LimmaTech Biologics, and Vaccine Company, all of which operate in the infectious disease space. And those are just the most recent examples; there are more.
Eli Lilly's future is in its acquisitions
No single deal is all that significant. However, taken together, they show that Eli Lilly is attempting to broaden its therapeutic footprint as it prepares for the day when GLP-1 weight-loss drugs are no longer the revenue and earnings drivers they are today. You should be paying as much attention to Eli Lilly's acquisition spree as you do to its GLP-1 drugs. The impact won't be felt today, but these deals are what will, eventually, drive the company's future.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 7, 2026.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly, Novo Nordisk, and Pfizer. The Motley Fool has a disclosure policy.

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

Eli Lilly LLY and Johnson & Johnson JNJ are two leading U.S.-based healthcare companies with strong positions across the pharmaceutical and biotech industries.
Both companies have significant exposure to oncology, immunology and neuroscience. J&J’s business is more diversified, with treatments targeting cardiovascular and metabolic conditions, pulmonary hypertension and infectious diseases, along with a sizable medical devices operation. Lilly, meanwhile, has built a leading position in cardiometabolic care, fueled by its GLP-1 portfolio, with Mounjaro and Zepbound serving as major growth engines.
Both companies continue to deliver strong revenue and earnings growth and have promising long-term prospects. However, which stock presents the more attractive investment opportunity at current levels? An assessment of their fundamentals, growth potential, valuations and key risks can help determine which one offers the better risk-reward profile.
The Case for Lilly Stock
Lilly has seen extraordinary momentum in its cardiometabolic franchise. Its blockbuster drugs, Mounjaro for type II diabetes and Zepbound for obesity, have become some of the fastest-growing medicines in pharmaceutical history, gaining from enormous global demand for GLP-1 therapies. These therapies account for around 65% of the company’s total revenues and have become key top-line drivers for Lilly, with demand rising rapidly. In the first half of 2026, the drugs generated combined sales of $27.6 billion.
Lilly’s newly launched once-daily oral GLP-1 pill, Foundayo (orforglipron), for treating obesity, can prove to be a commercial game-changer for Lilly. Oral pills will be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Zepbound and rival Novo Nordisk’s NVO Wegovy. Foundayo's launch uptake has been encouraging as Lilly expands physician engagement and direct-to-consumer promotion in the United States.
To maintain leadership in the GLP-1 market, Lilly is developing several next-generation, more powerful and more convenient GLP-1–based treatments, including oral options and multi-acting candidates. Retatrutide is one of Lilly’s most important late-stage pipeline candidates, targeting GLP-1, GIP and glucagon pathways and potentially delivering greater weight loss and broader metabolic benefits than current therapies. With late-stage studies spanning obesity, type II diabetes, obstructive sleep apnea (OSA) and other indications, Lilly plans to seek FDA approval in the first quarter of 2027, potentially creating another multibillion-dollar growth driver.
Lilly’s growth story is increasingly diversified beyond its GLP-1 franchise, with newer therapies such as Omvoh, Jaypirca, Ebglyss, Kisunla and Inluriyo gaining traction across multiple therapeutic areas. These products are becoming meaningful growth contributors.
The company has also embarked on an aggressive M&A spree in the past couple of years, acquiring biotech companies across oncology, neuroscience, cardiovascular disease, gene editing, inflammation, cell therapy and vaccines to diversify its long-term growth drivers beyond GLP-1 therapies. The company has announced around 10 small biotech M&A deals this year.
Lilly has its share of problems. Prices of most of Lilly’s products are declining in the United States. Price is expected to continue to be a drag on top-line growth in the low- to mid-teens percentage in 2026. Rising competition in the GLP-1 diabetes/obesity market is a key headwind. Also, sales of late-life cycle products like Trulicity, Taltz and Verzenio are expected to be flat to down in 2026.
The Case for J&J Stock
J&J’s biggest strength is its diversified business model, operating through pharmaceuticals and medical devices divisions, which reduces dependence on any single product or market. It has more than 275 subsidiaries and boasts 28 platforms or products with more than $1 billion in annual sales, with the aim of adding even more. Its diversification helps it to withstand economic cycles more effectively. It also boasts strong cash flows and has increased its dividends for 64 consecutive years. J&J believes the depth of its portfolio and pipeline is stronger than ever.
J&J’s Innovative Medicines segment is the company’s primary growth engine. Innovative Medicine segment sales rose 6.2% organically in the first half of 2026, despite the loss of exclusivity (LOE) of the blockbuster drug, Stelara. Growth was driven by J&J’s key drugs like Darzalex, Erleada and Tremfya. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato also contributed significantly to growth.
J&J’s MedTech growth slowed in the second quarter, reflecting weakness in Cardiovascular, particularly Abiomed due to slow procedure volumes, and continued China VBP headwinds.
J&J’s new cancer drugs, Carvykti, Tecvayli, Talvey and Rybrevant/Lazcluze are contributing significantly to top-line growth, driven by market share gains. Its recent pipeline launches, including Inlexzo, Imaavy and Icotyde, are gaining traction and could become significant growth drivers in future quarters.
J&J believes 10 of its new products in the Innovative Medicine segment have the potential to reach peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta, Inlexzo, Rybrevant, plus Lazcluze and Icotyde.
J&J expects 2026 to be a year of accelerated growth. The company is confident that it can achieve its target of generating more than $100 billion in revenues in 2026 with $49.4 billion already generated in the first half. It expects sales to continue to improve in 2027, with a “line of sight” to double-digit growth by the end of the decade. J&J believes that it is already achieving this growth. Though J&J’s total revenues are currently rising in a mid-single-digit range, excluding Stelara, J&J’s top line grew in a double-digit range in both the first and second quarters of 2026.
J&J also expects its MedTech business to do better in the second half of the year compared with the first, driven by strength in Vision, Orthopedics, Surgery and better performance in Cardiovascular. While the Abiomed softness creates a new overhang, it accounts for less than 2% of sales, and J&J has other top-line drivers to compensate.
However, J&J faces its share of headwinds, including the Stelara patent cliff, the upcoming LOE of key drugs Opsumit and Simponi, and softness in MedTech. The legal battle surrounding its talc lawsuits is another headwind. Though the issue is close to resolution, it has not yet been fully resolved.
How Do Estimates Compare for LLY & JNJ?
The Zacks Consensus Estimate for LLY’s 2026 sales and EPS implies a year-over-year increase of 35.4% and 48.4%, respectively. The Zacks Consensus Estimate for 2026 has risen from $35.56 to $35.93 per share over the past 60 days, while that for 2027 has risen from $44.58 to $45.93 per share over the same timeframe.
LLY Estimate Movement
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for J&J’s 2026 sales and EPS implies a year-over-year increase of 7.3% and 7.4%, respectively. The Zacks Consensus Estimate for 2026 earnings has risen from $11.58 to $11.59 over the past 60 days, while that for 2027 earnings has gone up from $12.65 per share to $12.80 over the same time frame.
JNJ Estimate Movement
Image Source: Zacks Investment Research
Price Performance and Valuation of LLY & JNJ
So far this year, LLY’s stock has risen 6.9% and J&J’s stock has surged 33%. The industry has jumped 14.5% in the same time frame.
Image Source: Zacks Investment Research
J&J looks more attractive than Lilly from a valuation standpoint. Going by the price/earnings ratio, Lilly’s shares currently trade at 26.87 forward earnings, significantly higher than 18.71 for the industry. However, LLY’s stock is trading below its 5-year mean of 34.57. J&J’s shares currently trade at 22.16 forward earnings, higher than the industry as well as the stock’s 5-year mean of 15.65.
Image Source: Zacks Investment Research
J&J’s dividend yield is around 2%, while Lilly’s is around 0.6%.
Image Source: Zacks Investment Research
LLY or JNJ: Which is a Better Pick?
J&J enjoys a diversified revenue base, a large cash-generating business and a long history of returning capital to shareholders. It is witnessing steady sales and earnings growth, continued strength in its Innovative Medicine business, and improving fundamentals and outlook. Despite several headwinds, J&J looks quite confident that it will be able to navigate these challenges.
Lilly remains one of the most compelling growth stories in the pharmaceutical industry, supported by its significant price appreciation, dominant position in the rapidly expanding obesity and diabetes markets, a diversified late-stage pipeline and strong financial performance.
Choosing between Eli Lilly and J&J is probably the most difficult choice to make among large drug stocks. Both have seen steady growth in sales and earnings, rising stock prices and analyst estimates and have an optimistic outlook for future growth. Additionally, continued pipeline advancements, favorable regulatory developments, and strategic M&A activity have strengthened investor sentiment for both stocks.
Both stocks have a Zacks Rank #3 (Hold). However, we are selecting Lilly over J&J as the stock offers a substantially stronger long-term earnings-growth opportunity. While JNJ’s share price movement and valuation are slightly better, LLY’s long-term growth prospects remain among the strongest in the healthcare sector. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).

Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?

(RTTNews) - Novo Nordisk (NVO, NOVOB.CO, NOV.DE) announced first results from the STEP Young phase 3 trial, evaluating once-weekly semaglutide in combination with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years old with obesity. The results showed that 40.4% of those treated with semaglutide were no longer classified as having obesity at week 68, compared with none of those treated with placebo.
The company will present detailed STEP Young results at The Obesity Society's annual meeting ObesityWeek 2026, 14-17 November in Washington DC, United States.
At last close on NYSE, Novo Nordisk shares were trading at $46.60.
For More Such Health News, visit rttnews.com.

Novo Nordisk: STEP Young Phase 3 Trial With Semaglutide Shows Superior BMI Reduction At Week 68

Key Points
Viking Therapeutics has significant upside potential based on Wall Street targets.
VK2735's dual-formulation strategy could differentiate it in a crowded obesity drug market, but it faces major risks, including strong competition and safety concerns with the oral formulation.
According to Yahoo! Finance, the consensus price target from analysts for Viking Therapeutics (NASDAQ: VKTX) is about $92, which indicates potential upside of 162% from its current stock price. It's a significant opportunity, but is it justified? Here's the lowdown from the skeptics' perspective.
Viking Therapeutics' prospects
The investment case for the stock rests on its lead drug candidate, VK2735, a dual GLP-1 and GIP agonist in development for obesity and type 2 diabetes. The two key advantages VK2735 may have over its rivals are a steeper rate of weight loss and the promise of a dual-formulation therapy (oral and subcutaneous). The combination of these two advantages would mean that patients could achieve significant weight loss with a subcutaneous (injectable) dose, followed by a more convenient oral maintenance dose.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
These properties mean VK2735 could win market share in a crowded field, and investors are looking forward to the results of its phase 3 trials of VK2735 in subcutaneous formulation (likely in the second half of 2027) and VK2735 in oral formulation (set to commence later this year with results likely in 2028/2029). In addition, investors are awaiting the imminent results of a small (180 adults) phase 1 maintenance trial designed to evaluate dosing regimens.
The skeptics' case for Viking Therapeutics
As with clinical-stage biopharmaceutical companies, there are two key considerations for investors to ponder, both of which pose risks for Viking Therapeutics. The first is competition from rival drugmakers and its possible impact on the market potential of Viking's pharmaceuticals. The second is Viking's success in its clinical trials, as that will also determine the value of its pipeline.
The obesity and type 2 diabetes treatment market is highly competitive, with drugs already within VK2735's class of drugs, including oral formulations. Moreover, much larger peers like Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Amgen are already developing next-generation or differentiated treatments.
Focusing on the more lucrative obesity market, the list of already approved drugs includes Eli Lilly's Zepbound (tirzepatide), which has the same mechanism as VK2735, and an oral tablet, Foundayo (orforglipron). Novo Nordisk has semaglutide approved as an injectable (Wegovy) for obesity and as an oral tablet (Rybelsus) for diabetes, with additional oral formulations for obesity in development.
Looking ahead, Eli Lilly plans to file for FDA approval of its GLP-1, GIP, and glucagon agonist, retatrutide, in early 2027, following several successful phase 3 trials. Novo Nordisk has CagriSema (which combines semaglutide and another drug) and an experimental drug, Amycretin, in phase 3 trials.
This is a highly competitive market, and it could be even more competitive by the time Viking completes its phase 3 trials for VK2735.
Clinical trial data
There is no end to reasons for trial failures. In the case of VK2735, it could come down to the safety and tolerability of the drug in oral form.
The stock crashed last summer after phase 2 results for VK2735 (oral) revealed a 20% discontinuation rate due to adverse events in the treated group. Oral formulations always have to answer the questions around potential gastrointestinal issues.
Any issue with the tolerability of VK2735 (oral) will threaten not only the market potential of the oral formulation itself but also its use as a maintenance dose in Viking's dual-formulation approach.
Where next for Viking Therapeutics
There's no doubt the company faces significant competitive and clinical trial risks, and investors are hoping Viking calibrates any titration issues with the oral formulation in the phase 3 trial. In the near term, the results from the phase 1 maintenance trial will provide indicative data on the potential dual-formulation strategy. A successful result may cause some skeptics to reconsider their position.
Should you buy stock in Viking Therapeutics right now?
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 5, 2026.
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen, Eli Lilly, and Novo Nordisk. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.

Key Points
Intuitive Surgical's latest version of the da Vinci system could unlock important opportunities.
Novo Nordisk is still well-positioned to cash in on the GLP-1 market.
Broader equities have performed fairly well this year, despite several macroeconomic headwinds, with major U.S. indexes now sitting near all-time highs. Is it still worth it to invest in stocks right now? Yes, it is, and one way to do so is to look for beaten-down companies that look likely to recover. Here are two options to consider: Intuitive Surgical (NASDAQ: ISRG) and Novo Nordisk (NYSE: NVO). Despite recent challenges, both of these corporations look like great long-term picks.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
1. Intuitive Surgical
Intuitive Surgical's latest version (the fifth) of its famous da Vinci system is popular among surgeons. However, the device carries lower margins than the company's average. That's one of the key reasons the stock has underperformed in recent years and is down 34% year to date. But Intuitive Surgical may be a great buy on the dip, as the da Vinci 5 is likely to make up for its lower margins down the road.
The device could meaningfully expand Intuitive Surgical's market thanks to several features that previous versions lacked. For instance, the da Vinci 5's Force Feedback Technology allows surgeons to better gauge the force they exert on patients' tissues during procedures, potentially improving outcomes. The device also has significantly greater computing capacity than older da Vinci systems and could eventually integrate many artificial intelligence (AI)-powered features.
No wonder it's been helping Intuitive Surgical expand its installed base.
In the second quarter, the company sold 468 da Vinci systems, 246 of which were da Vinci 5 systems. It brought the total installed base of its crown jewel to 11,710, up 12% year over year. Intuitive Surgical makes most of its money from the sale of perishable instruments and accessories. Increased procedure volume yields stronger recurring, higher-margin revenue from this source. And over the medium term, the da Vinci 5 could meaningfully grow procedure volume.
Further, the company could also reduce manufacturing costs associated with the da Vinci 5 -- thereby improving its margins -- as it scales production. Intuitive Surgical is still looking at a large addressable market in the robotic-assisted surgery industry, which is arguably underpenetrated. The company also boasts a wide moat thanks to high switching costs. Intuitive Surgical can bounce back from recent challenges and reward patient investors, which makes the stock a solid buy on the dip.
2. Novo Nordisk
Novo Nordisk was a pioneer in the GLP-1 weight loss market. But the company has lost its lead to its biggest rival, Eli Lilly (NYSE: LLY). The Denmark-based pharmaceutical leader's financial results have been mediocre over the past couple of years. The stock is down substantially as a result, having lost 8% in value this year alone. The good news for Novo Nordisk is that after a series of clinical setbacks in its core area of expertise, the company appears ready to turn things around.
The drugmaker's future still largely hinges on its work in the GLP-1 market, and it boasts a deep pipeline in this field. Clinical wins over the next couple of years could send the stock price soaring. Let's discuss two of Novo Nordisk's most promising candidates. First, there is amycretin, a medicine that mimics the actions of the GLP-1 and amylin hormones. It posted highly promising results in a phase 1b/2a study. Patients on amycretin lost as much as 24.3% of their weight in 36 weeks. These are outstanding results, albeit in a study with a relatively small number of patients.
The medicine also posted excellent weight loss and A1C level reductions in patients with type 2 diabetes (who have a harder time losing weight). Further, this promising candidate is being developed in both subcutaneous and oral formulations. Then there is UBT251, which mimics the action of three gut hormones: GLP-1, GIP, and glucagon. It posted a mean weight loss of up to 19.7% in a 24-week phase 2 study in China.
Again, there are caveats to keep in mind here, but these two candidates could help Novo Nordisk regain some market share in its core therapeutic area. Of note, the company has already made progress with the Wegovy pill, the first oral GLP-1 weight-loss medicine to earn approval. It has a leading market share in the oral weight loss niche. The GLP-1 market is projected to grow rapidly, and Novo Nordisk appears well-positioned to capitalize on it. That's why the stock is a buy as it remains well below its all-time highs.
Should you buy stock in Intuitive Surgical right now?
Before you buy stock in Intuitive Surgical, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intuitive Surgical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $445,833!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,402,153!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 4, 2026.
Prosper Junior Bakiny has positions in Eli Lilly, Intuitive Surgical, and Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly, Intuitive Surgical, and Novo Nordisk. The Motley Fool recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Indicator	TTM Median
P/E	11.01 21.70
Price/Sales	3.96 3.10
P/B	6.89 2.54
P/FCF	21.56 19.03

Indicator	TTM Median
ROE	67.11 19.44
ROA	23.53 7.04
ROI	42.91 9.42
Net Worth	201.69 0.24
Quick Ratio	0.56 1.71
Current Ratio	0.79 2.85

Indicator	TTM Median
Net Profit Margin	37.33 10.99
Operating Margin	45.53 14.14
Gross Margin	81.92 75.17
Return on tangible equity	189.14 41.48

Indicator	TTM Median
EPS	0.71 0.46
EPS Forecast	0.66 0.37
Revenue	15.16B 19.00M
Gross Profit	13.03B —
EBITDA	9.89B —

Novo Nordisk A/S

Recent quarterly and TTM performance

Valuation

Debts

Efficiency

Other ratios

Revenue